CMMB logo

Chemomab Therapeutics (CMMB) Operating Profit

Annual Operating Profit

-$25.46 M
+$3.07 M+10.77%

31 December 2023

CMMB Operating Profit Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly Operating Profit

-$3.71 M
+$58.00 K+1.54%

01 September 2024

CMMB Quarterly Operating Profit Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

TTM Operating Profit

-$15.37 M
+$657.00 K+4.10%

01 September 2024

CMMB TTM Operating Profit Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

CMMB Operating Profit Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+10.8%+15.0%+49.2%
3 y3 years-326.3%-28.3%-65.6%
5 y5 years---

CMMB Operating Profit High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3 years-326.3%+10.8%-28.3%+59.0%-65.6%+55.0%
5 y5 years-326.3%+10.8%-237.0%+59.0%-802.2%+55.0%
alltimeall time-326.3%+10.8%-237.0%+59.0%-802.2%+55.0%

Chemomab Therapeutics Operating Profit History

DateAnnualQuarterlyTTM
Sept 2024
-
-$3.71 M(-1.5%)
-$15.37 M(-4.1%)
June 2024
-
-$3.77 M(-6.9%)
-$16.03 M(-21.6%)
Mar 2024
-
-$4.05 M(+5.2%)
-$20.46 M(-19.6%)
Dec 2023
-$25.46 M(-10.8%)
-$3.85 M(-11.9%)
-$25.46 M(-15.8%)
Sept 2023
-
-$4.37 M(-46.7%)
-$30.25 M(-11.5%)
June 2023
-
-$8.20 M(-9.4%)
-$34.20 M(+6.0%)
Mar 2023
-
-$9.05 M(+4.7%)
-$32.26 M(+13.1%)
Dec 2022
-$28.53 M
-$8.64 M(+3.9%)
-$28.53 M(+14.5%)
Sept 2022
-
-$8.32 M(+33.0%)
-$24.91 M(+27.8%)
DateAnnualQuarterlyTTM
June 2022
-
-$6.25 M(+17.6%)
-$19.49 M(+21.9%)
Mar 2022
-
-$5.32 M(+5.9%)
-$15.99 M(+29.3%)
Dec 2021
-$12.37 M(+107.1%)
-$5.02 M(+73.8%)
-$12.37 M(+33.2%)
Sept 2021
-
-$2.89 M(+5.0%)
-$9.29 M(+21.9%)
June 2021
-
-$2.75 M(+62.0%)
-$7.62 M(+27.7%)
Mar 2021
-
-$1.70 M(-12.5%)
-$5.97 M(-0.1%)
Dec 2020
-$5.97 M
-$1.94 M(+58.5%)
-$5.97 M(+48.2%)
Sept 2020
-
-$1.23 M(+11.3%)
-$4.03 M(+43.7%)
June 2020
-
-$1.10 M(-35.4%)
-$2.81 M(+64.6%)
Mar 2020
-
-$1.70 M
-$1.70 M

FAQ

  • What is Chemomab Therapeutics annual operaing income?
  • What is the all time high annual operating profit for Chemomab Therapeutics?
  • What is Chemomab Therapeutics annual operating profit year-on-year change?
  • What is Chemomab Therapeutics quarterly operating income?
  • What is the all time high quarterly operating profit for Chemomab Therapeutics?
  • What is Chemomab Therapeutics quarterly operating profit year-on-year change?
  • What is Chemomab Therapeutics TTM operating income?
  • What is the all time high TTM operating profit for Chemomab Therapeutics?
  • What is Chemomab Therapeutics TTM operating profit year-on-year change?

What is Chemomab Therapeutics annual operaing income?

The current annual operating profit of CMMB is -$25.46 M

What is the all time high annual operating profit for Chemomab Therapeutics?

Chemomab Therapeutics all-time high annual operaing income is -$5.97 M

What is Chemomab Therapeutics annual operating profit year-on-year change?

Over the past year, CMMB annual operaing income has changed by +$3.07 M (+10.77%)

What is Chemomab Therapeutics quarterly operating income?

The current quarterly operating profit of CMMB is -$3.71 M

What is the all time high quarterly operating profit for Chemomab Therapeutics?

Chemomab Therapeutics all-time high quarterly operating income is -$1.10 M

What is Chemomab Therapeutics quarterly operating profit year-on-year change?

Over the past year, CMMB quarterly operating income has changed by +$657.00 K (+15.04%)

What is Chemomab Therapeutics TTM operating income?

The current TTM operating profit of CMMB is -$15.37 M

What is the all time high TTM operating profit for Chemomab Therapeutics?

Chemomab Therapeutics all-time high TTM operating income is -$1.70 M

What is Chemomab Therapeutics TTM operating profit year-on-year change?

Over the past year, CMMB TTM operating income has changed by +$14.88 M (+49.18%)